Nakom (Carbidopa, Levodopa)

Carbidopa/Levodopa, the active ingredient in Nakom, is a dopamine precursor presented as an oral tablet for oral use. It is employed to manage the motor symptoms of Parkinson's disease and related Parkinsonian syndromes in adult patients. It is indicated for patients who require continuous dopaminergic stimulation to improve gait, rigidity and tremor, and is often combined with other adjunctive therapies.

GNH USA supplies Nakom as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to multiple regions.

Carbidopa/Levodopa is used in the management of Parkinsonian disorders by restoring central dopamine levels. - Parkinson's disease: reduces motor fluctuations and improves gait, rigidity, and tremor. - Parkinsonian syndrome: alleviates symptoms when Parkinson's disease is secondary to other causes. - Rest tremor associated with Parkinson's disease: diminishes tremor amplitude and frequency. - Secondary Parkinsonism: improves motor function in drug‑induced or vascular Parkinsonism.

Carbidopa/Levodopa may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: feeling of sickness often occurring after the first doses. - Dizziness: light‑headed sensation, especially when standing quickly. - Headache: mild to moderate pain in the head region. - Constipation: reduced bowel movements and hard stools.

Serious or Rare Side Effects: - Dyskinesia: involuntary, erratic movements that may affect limbs or facial muscles. - Hallucinations: visual or auditory disturbances that can be distressing. - Severe hypotension: marked drop in blood pressure leading to fainting or falls.

When prescribing Carbidopa/Levodopa, clinicians should consider several precautionary measures to ensure safe use. - Monitor blood pressure: check regularly for orthostatic hypotension, especially during dose titration. - Assess liver function: evaluate hepatic enzymes before initiation and periodically during therapy. - Review concomitant medications: avoid concurrent use of MAO‑B inhibitors and dopamine antagonists. - Educate patient on diet: maintain consistent protein intake to prevent fluctuations in drug absorption. - Adjust dose in renal impairment: consider reduced dosing or increased monitoring in patients with decreased renal function. - Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Carbidopa/Levodopa interacts with several medicines; awareness of these interactions helps avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - MAO‑B inhibitors: risk of hypertensive crisis or severe serotonin syndrome; should not be co‑administered. - Non‑selective MAO inhibitors: can cause dangerous hypertensive reactions; avoid concurrent use. - Antipsychotics with dopamine antagonism (e.g., haloperidol): may markedly diminish therapeutic effect. - Antiemetics that block dopamine receptors (e.g., metoclopramide): can reduce levodopa absorption and efficacy.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure‑lowering effect may require dose adjustment. - SSRIs or SNRIs: potential for serotonin syndrome; monitor patient for symptoms.